A CRUSADE-adjusted prospective cohort analysis of heparin dosing velocity, multivariable mediation and iatrogenic haemorrhage in acute coronary syndromes
References
- Collet JP, Thiele H, Barbato E, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826.
- Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the management of patients with acute coronary syndromes. J Am Coll Cardiol. 2025;85(1):e1–e198.
- Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: current challenges and future directions. J Thromb Haemost. 2022;20(8):1737–1745.
- Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S–e43S. doi:10.1378/chest.11-2291.
- Maier CL, Connors JM, Levy JH. Troubleshooting heparin resistance. Hematology Am Soc Hematol Educ Program. 2024;2024(1):186–193. doi:10.1182/hematology.2024000659.
- Mina A, Favaloro EJ, Mohammed S, Koutts J. Elevated factor VIII levels and arterial thrombosis: a systematic review. Thromb Res. 2022;218:128–138.
- Tan K, et al. Acute phase reactants and coagulation assay interference: clinical implications for cardiovascular care. Clin Chem. 2024;70(1):15–22.
- Zhao Y, et al. Impact of C-reactive protein on anticoagulation monitoring in critically ill patients. J Cardiothorac Vasc Anesth. 2024;39(1):248–256.
- Sun L, Zhao J, Jiang G, Lu W, Rong H, Lun L, et al. In-house chromogenic anti-factor Xa assay: development, validation, and identification of factors predicting APTT discordance. Front Med (Lausanne). 2026;12:1745447. doi:10.3389/fmed.2025.1745447.
- Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg/kg and 10-mg/kg heparin bolus doses for initiation of heparin anticoagulation. Arch Intern Med. 2004;164(15):1669–1673.
- Bolliger D, Erdoes G, Mauermann E. Heparin resistance: definition, risk factors, and therapeutic approaches. J Cardiothorac Vasc Anesth. 2025;39(1):448–456.
- Kashyap U, et al. Heparin resistance in the ICU: mechanisms and management. Angiology. 2024;75(4):332–345.
- Barletta JF, DeYoung JL, McAnna VF, Mccarthy HL, Anderson RC. Relationship between weight-based heparin dosing and bleeding in obese versus non-obese patients. J Thromb Thrombolysis. 2017;43(4):495–500.
- Morgovan C, Frum A, Stoicescu L, Butuca A, Dobrea CM, Arseniu AM, et al. An overview of anticoagulant drugs pharmacology, therapeutic approaches, limitations and perspectives. Pharmaceutics. 2026;18(2):163. doi:10.3390/pharmaceutics18020163.
- Moschitto M, Granger CB, Ohman EM, et al. Reassessing the value of the aPTT for heparin monitoring in acute coronary syndromes. Am Heart J. 2020;228:21–30.
- Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation. 2009;119(14):1873–1882. doi:10.1161/CIRCULATIONAHA.108.828541.
- Fanaroff AC, et al. CRUSADE bleeding score as a predictor of bleeding events in patients with acute coronary syndrome: systematic review and meta-analysis. Heart Lung Circ. 2021;30(4):517–525.
- Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–269.
- World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194.
- Lindahl B, et al. Markers of inflammation and outcomes in acute coronary syndromes: a systematic review. Circulation. 2023;148(16):1254–1268.
- Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol. 2008;51(7):701–707. doi:10.1016/j.jacc.2007.10.034.
- Mehran R, et al. Bleeding Academic Research Consortium (BARC) definitions. Circulation. 2011;123(23):2736–2747.
- Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786.
- Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research. J Pers Soc Psychol. 1986;51(6):1173–1182. doi:10.1037//0022-3514.51.6.1173.
- Price E, et al. Anti-Factor Xa versus aPTT: a comparative review for heparin monitoring. Am J Health-Syst Pharm. 2025;82(3):215–225.
- Nguyen H, et al. Precision monitoring of unfractionated heparin in the intensive care unit. Chest. 2024;165(1):180–190.
- Jonas M, Hirsch A, Neuhaus KL, et al. Anti-Xa versus aPTT monitoring of unfractionated heparin in patients with acute coronary syndromes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2024;10(6):580–590.
- Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.2307/2670170.
Language: English
Published on: Sep 23, 2026
Published by: Romanian Society of Cardiology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Hasan Ali Farhan, Hussein AlKenzawi, Hayder Ali Majeed, Abbas Zuhair Marouf, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.